E. Thompson

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

S. Corti, M. Pane, E. Mercuri, 2021, The Lancet Neurology.